uz
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Kanalga Telegramโ€™da oโ€˜tish

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Ko'proq ko'rsatish

๐Ÿ“ˆ Telegram kanali ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ analitikasi

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 232 obunachidan iborat bo'lib, Tibbiyot toifasida 1 940-o'rinni va Saudiya Arabistoni mintaqasida 5 740-o'rinni egallagan.

๐Ÿ“Š Auditoriya koโ€˜rsatkichlari va dinamika

ะฝะตะฒั–ะดะพะผะพ sanasidan buyon loyiha tez oโ€˜sib, 13 232 obunachiga ega boโ€˜ldi.

04 Iyul, 2026 dagi oxirgi maโ€™lumotlarga koโ€˜ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 96 ga, soโ€˜nggi 24 soatda esa -10 ga oโ€˜zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya oโ€˜rtacha 27.57% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 6.73% ini tashkil etuvchi reaksiyalarni toโ€˜playdi.
  • Post qamrovi: Har bir post oโ€˜rtacha 3 650 marta koโ€˜riladi; birinchi sutkada odatda 891 ta koโ€˜rish yigโ€˜iladi.
  • Reaksiyalar va oโ€˜zaro taโ€™sir: Auditoriya faol: har bir postga oโ€˜rtacha 45 ta reaksiya keladi.
  • Tematik yoโ€˜nalishlar: Kontent ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ kabi asosiy mavzularga jamlangan.

๐Ÿ“ Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida taโ€™riflaydi:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Yuqori yangilanish chastotasi (oxirgi maโ€™lumot 05 Iyul, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli boโ€˜lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim taโ€™sir nuqtasiga aylantirishini koโ€˜rsatadi.

13 232
Obunachilar
-1024 soatlar
-1367 kunlar
+9630 kunlar
Postlar arxiv
Pharmacology Lippincott 7th -Copy (1) export (689370891).pdf9.30 MB

#ุชูุฑูŠุบุงุช

ุจู‚ู‰ ุงู„ digoxin ูˆู†ูƒู…ู„ ุงู„ุฌุงุจุชุฑ ู„ุงุฒู… ุจุงุฑุช ู„ูˆุญุฏู‡ ู‡ุฐุง ุงู„ุนุฒูŠุฒ๐Ÿ˜ ุงู† ุดุงุก ุงู„ู„ู‡ ุงู„ูŠูˆู… ุงูƒู…ู„ู‡

ACC/AHA Classification OF Heart failure
ACC/AHA Classification OF Heart failure

ุดุจุงุจ ู…ุฑุถ ุจุงุฑูƒู†ุณูˆู† ูˆ ุงู„ุฒู‡ุงูŠู…ุฑ ูˆุงู„ุชุตู„ุจ ุงู„ู…ุชุนุฏุฏ ูƒู„ู‡ู† ุจุฌุงุจุชุฑ ูˆุงุญุฏ ุงุณู…ู‡ Neurodegenerative Diseases ูŠุนู†ูŠ ู…ูˆุฌูˆุฏ ุดุฑุญู‡ู† ู‡ู†ุง ุจุงู„ุฑุณุงู„ุฉ ุงู„ู…ุซุจุชุฉ ุฑู‚ู… 5

ุดุจุงุจ ุจุงู„ู†ุณุจุฉ ู„ #ุชูุฑูŠุบุงุช ุชุดู…ู„ ู…ู„ุฎุตุงุช ู„ุจุนุถ ุงู„ุฌุงุจุชุฑุงุช ูˆ ุงู„ุฑุณูˆู… ุงู„ุชูˆุถูŠุญูŠุฉ ุงุซู†ุงุก ุดุฑุญูŠ ูˆุจุนุถ ุงู„ู…ู„ุงุญุธุงุช ุงู„ูŠ ู…ู…ูƒู† ุชููŠุฏูƒู… ุงู…ุง #ุฑุงุจุนุฉ ูŠุดู…ู„ ู…ุตุงุฏุฑ ุงู„ู…ุฑุญู„ุฉ ุงู„ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„

Pharmacology Lippincott 7th -Copy (1) export (306695961).pdf9.27 MB

ุชุฃุฎุฑุช ุตุญ ูˆูƒู„ู‡ ู…ู† ูˆุฑู‡ ุงู„ุงูู„ุงูˆู†ุฒุง ุงุฎุฑุชู†ูŠ๐Ÿค• ุจุณ ู…ุณุชู…ุฑ ูˆูŠุงูƒู… ุงู† ุดุงุก ุงู„ู„ู‡

Difference between UC and CD #ุชูุฑูŠุบุงุช
Difference between UC and CD #ุชูุฑูŠุบุงุช